Tildrakizumab effectiveness related to trial results
After 12 weeks of treatment with tildrakizumab (Ilumya), over 50 percent of patients can be cleared of their psoriasis. This biologic drug was approved in Canada in October 2021. In clinical dermatology experience, after one month of therapy with this interleukin-23 (IL-23) medication, a high majority of psoriasis patients experienced improvement in their symptoms. In research and real-life settings, tildrakizumab has been shown to be safe and offer long-term effectiveness.
